Coming soon! Dr. Ebos @ebos.bsky.social will be presenting in our @sinclaircri.bsky.social seminar series on Feb 26 at 4 PM. Questions? Send us an email: [email protected] #ResearchTalk #SeminarAlert #CancerResearch #CancerDrugResistance @queensuhealth.bsky.social @queensuresearch.bsky.social

Follow up to Doug Hanahan’s visionary article about the stages of cancer development from back in the 1990s www.cell.com/cell/fulltex...

Thank you to the American Cancer Society for highlighting our lab, this means a great deal. Please join the Making Strides Against Breast Cancer Fundraiser October 17, 2026 www.facebook.com/groups/makin...

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg

🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding. Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!

#Review 🕯️🕯️🕯️ The ability of #macrophages to eliminate cancer cells is controlled by phagocytic checkpoints. Veillette&Co discuss targeting these checkpoints for cancer therapy and outline strategies to address therapeutic efficacy concerns. 📖⬇️

Review: Linking tumour angiogenesis and tumour immunity

How can senescent cells, which are damaged and growth arrested, both block tumor initiation as well as fuel its growth? A recent study published in Cancer Discovery @aacrjournals.bsky.social from Lin Zhou in the lab uncovered some new insights into this puzzle. aacrjournals.org/cancerdiscov...

For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms rdcu.be/eLS8A www.nature.com/articles/s41...

🚀 NY-CURES Launch — Championing State-Wide Investment in Science! 🚀 Our new coalition advocates for sustained public support of New York’s vibrant biomedical research ecosystem — creating cures, economic gains & strengthening communities. Sign up. Stay informed. Join the movement: www.nycures.org/

Review: Targeting the peripheral neural-tumour microenvironment for cancer therapy

Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling 🧪 #PancreaticCancer gut.bmj.com/content/74/9...

Happy to share our @bio-protocol.bsky.social describing an ex vivo method to measure CD8+ T-cell function. This was used in our recent papers in @emboreports.org (2025) and Molecular Cancer Therapeutics (2024). Thanks to Melissa Dolan for leading this effort - Congratulations to the whole team!

TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation @cp-cellrepmed.bsky.social @mklevings.bsky.social cell.com/cell-reports...

It’s out!!!!! We hope our review on aging, immunity, and cancer is helpful. Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support

The appearance of large language models caused a drastic shift in the vocabulary of academic writing, according to an analysis in #ScienceAdvances of more than 15 million biomedical abstracts published from 2010 to 2024. Learn more:

Editorial: Immune modulation and angiogenesis in regenerative and developmental processes.

How multispecific molecules are transforming pharmacotherapy www.nature.com/articles/s41... rdcu.be/ezbK0 This new article by Raymond Deshaies discusses how a wave of drugs designed to engage two or more entities are overcoming development barriers such as toxicity, rapid clearance and redundancy

Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors

Two common forms of cancer therapy can (in some cases) lead to further metastatic cancer themselves. What to do to fix that:

Multiple sclerosis is regulated by myelin-specific T cells, but the specific mechanism is unclear Hughes et al. now show that the transcriptional coregulator OCA-B promotes pathogenic maturation of stem-like CD4+ T cells and autoimmunity in mouse models of MS: buff.ly/BWdztxJ

Pan-cancer human brain metastases atlas at single-cell resolution

Spotlight @cp-trendsimmuno.bsky.social Repurposing of old drugs for unleashing innate immunity www.cell.com/trends/immun...

Emerging ‘co-scientist’ systems use artificial intelligence chatbots to mimic the deliberations of a research group. Nature asked researchers to test them out. Here’s what they learned. #Academicsky 🧪

Senolytics under scrutiny in the quest to slow aging - @jpsenescence.bsky.social bit.ly/4lzqTbc

Online Now: The dark side of radiotherapy

Review: Senescence in Cancer

Review: Acquired resistance to immunotherapy in solid tumors

Nature Reviews Cancer —Acquired resistance in cancer: towards targeted therapeutic strategies

PD-L1 and the dawn of modern cancer immunotherapy.

#Medsky🧪 #immunosky #oncosky #neurosky Up to 20 % of metastatic 🧠 tumors arise from primary BC www.nature.com/articles/s41... While primary #breastcancer is curable if caught early, metastatic tumors have significantly poorer survival rates. #Brainmetastases,

Great thread on day-to-day problem solving in the lab.

Applause to the Roswell Park teams that presented new #cancerresearch at today’s #AACR25 sessions – and thank you to the program alumni who stopped to reconnect! #innovationforimpact www.roswellpark.org/newsroom/202...

CAR-T therapy in solid tumors

🚨New Review available online Scott M. Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context. www.nature.com/articles/s43...

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer. 🔓 pubmed.ncbi.nlm.nih.gov/40196378/ @ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly

Review: Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma

They are cutting cancer research. They are cutting cancer research. They can deny it all they want, but they are cutting cancer research. These are the cuts being made the DoD CDMRP cancer funding mechanism www.fightcancer.org/sites/defaul...

Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma